2024-02-13T00:00:00.000+11:00
Ongoing

BeiGene BGB-11417-301

BeiGene BGB-11417-301
Lymphoma

A Phase 3, Open-label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia.

A Phase 3, Open-label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia.

Trial overview

Topic

Lymphoma

Trial registration

Number: NCT06073821

Study details

The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)

Further information

Please click here for more information

Location

GenesisCare North Shore – PI: Dr David Kilman

GenesisCare North Shore – PI: Dr David Kilman :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.